Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection

作     者：Yang Ke Le-Qun Li Jian-Hong Zhong Lin Wang 

作者机构：Department of Hepatobiliary SurgeryAffiliated Tumor Hospital of Guangxi Medical UniversityNanning 530021Guangxi Zhuang Autonomous RegionChina Department of Hepatobiliary SurgeryThe Second Affiliated Hospital of Kunming Medical UniversityKunming 650101Yunnan ProvinceChina 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2014年第6卷第9期

页      面：652-659页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Antiviral therapy Hepatitis B virus Hepatocellular carcinoma Liver resection Nucleos(t)ide analogue Survival rate 

摘      要：Significant advances have been made in nucleos(t)ideanalogue(NA) therapy to treat chronic hepatitis B,and this therapy reduces the risk of hepatitis B virus(HBV)-related hepatocellular carcinoma(HCC) in ***,whether NAs can also prevent recurrence after radical resection of HBV-related HCC remains controversial and is an important question,giventhat most patients will experience recurrence within afew years of curative *** we systematicallyreviewed the literature since 2004 on outcomes afteradministering NAs to patients with HBV-related HCCfollowing radical *** focused on treatmentindications,duration,effects on recurrence-free survivaland overall survival,and the management of NA *** find that patients with HCC should stronglyconsider NA therapy if they are positive for HBV-DNA,and that the available evidence suggests that postoperative NA therapy can increase both recurrence-free andoverall *** minimize drug resistance,cliniciansshould opt for potent analogues with higher resistancebarriers,and they should monitor the patient carefully for emergence of NA-resistant HBV.